S&P Biotech SPDR (XBI)
$151.73 1.70 (1.11%)
19:59 EST XBI Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 73.63M
PE Ratio -
Volume (Avg. Vol.) 4.13M
Day's Range 150.62 - 155.83
52-Week Range 62.94 - 155.83
Dividend & Yield 0.23 (0.15%)
XBI Stock Predictions, Articles, and S&P Biotech SPDR News
- From InvestorPlace
- From the Web
We’re again at the cusp of an amazing technological revolution that will carry the stock market to incredible new highs. Make sure to position yourself to take advantage of this huge profit potential.
Index funds offer investors the opportunity for diversified growth. With the S&P 500 and Dow Jones up so much in 2020, here are 7 others.
The novel coronavirus is weighing on the market, but these four biotech stocks can survive. Here's what you need to know to profit now.
Biotech stocks are winners this year, but there's still room to buy in for profit taking. ETFs such as IBB, XBI and XLV will continue to win.
Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
By Ken Trester
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
Biotech ETFs lagged in 2018, but that doesn't mean there aren't healthcare funds to consider for 2019.
As the Best ETFs contest enters its final quarter, there are a few contenders that could reasonably take the trophy for 2018.
As our Best ETFs for 2018 contest crosses into the second half of the year, a few contestants are really making standout gains, but others are making strong moves.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
While some of the contenders have been gravitating toward the top or bottom, it's still very much anyone's game in the Best ETFs for 2018 contest.